Eculizumab for Atypical Hemolytic Uremic Syndrome: Guidance for Developing Countries
Authors:
Open Access
- 30 July 2025
- journal article
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 35, 466-475
Abstract
Hemolytic uremic syndrome (HUS) is a heterogeneous group of disorders with the underlying pathology of thrombotic microangiopathy (TMA). With regional decline in Shiga toxin associated HUS, atypical HUS (aHUS) characterized by severe AKI, relapsing illness and extrarenal features, is increasingly identified. Since most such cases are mediated by dysregulation of the alternate complement pathway, the term complement-mediated TMA is preferred. Plasma exchanges (PEX) constitute the cornerstone of therapy of aHUS in developing countries, including for patients with anti-FH antibodies, the chief cause of pediatric aHUS in the subcontinent. However, worldwide experience with eculizumab during the past decade reports considerably better outcomes in patients with significant variants in genes encoding key complement regulators. With eculizumab poised to enter the Indian market, this article provides detailed guidance on its use. Indications for its rational use are discussed, including issues related to dosage, mode of administration, and side-effects of eculizumab and related agents. Therapy with eculizumab should be instituted promptly, with particular attention to dosage and frequency of administration. The article provides clear advice regarding meningococcal, pneumococcal and other vaccines, and the need for antibiotic prophylaxis during and following therapy with eculizumab. It also underscores key aspects for monitoring patients on complement blockade, and updates guidelines regarding discontinuation of complement inhibitors following remission, and in context of kidney transplantation. Both PEX and eculizumab are important options for managing patients with aHUS, with the choice dictated by the underlying cause, and ability to sustain either therapy in adequate doses and for sufficient duration for relapse-free outcomes.Keywords
This publication has 78 references indexed in Scilit:
- Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuriaAmerican Journal of Hematology, 2024
- Interventions for atypical haemolytic uraemic syndromeCochrane Database of Systematic Reviews, 2021
- Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech childrenEuropean Journal of Pediatrics, 2020
- Membrane‐filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safetyJournal of Clinical Apheresis, 2019
- The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndromePediatric Nephrology, 2016
- An international consensus approach to the management of atypical hemolytic uremic syndrome in childrenPediatric Nephrology, 2015
- An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndromePediatric Nephrology, 2014
- Successful treatment of DEAP-HUS with eculizumabPediatric Nephrology, 2013
- Use of eculizumab and plasma exchange in successful combined liver–kidney transplantation in a case of atypical HUS associated with complement factor H mutationPediatric Nephrology, 2013
- Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndromePediatric Nephrology, 2010